Trial Profile
A Study Evaluating Long-term-Outcome, Toxicity, Survival, and Quality-of-Life During Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients with Advanced Neuroendocrine Tumors
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2018
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- 27 Apr 2018 New trial record